BioCentury
ARTICLE | Clinical News

Vimpat regulatory update

December 22, 2016 5:25 PM UTC

The European Commission approved an expanded label for Vimpat lacosamide from UCB to include its use as monotherapy to treat partial-onset seizures in patients ages ≥16. Vimpat is approved in the EU a...